Huawei and Qualcomm Cross-License Across 5G, AI and Compute

On October 5, 2026, Huawei and Qualcomm announced a multi-year, broad patent license agreement. It has two parts: cross licenses to each company's patent portfolio across 5G, compute, AI and networking, and Qualcomm's purchase of certain Huawei U.S. patents in compute, AI, networking and other areas. The deal has not closed. Both parties say it will close after the necessary regulatory approvals arrive.

How a Patent Cross-License Works

A patent gives its owner the right to stop others from making or selling the claimed invention. A license is permission to do it anyway, usually in exchange for payment. In a cross-license, two companies each hold patents the other needs, so each grants the other access to its portfolio. This avoids a standoff in which both could sue, and it removes the risk that a product ships and later draws an infringement claim.

The announcement stresses 5G, and the reason is how mobile standards work. Cellular standards such as 4G and 5G are built from technologies that many companies contribute. A patent that any compliant device must use is called a standard-essential patent, or SEP. Because nobody can build a 5G phone without using them, SEP holders commit to licensing on fair, reasonable and non-discriminatory terms, known as FRAND. The companies say the agreement reflects licensing practices consistent with FRAND. Neither the source nor this article discloses the actual terms.

The second half of the deal is different in kind. Selling patents transfers ownership rather than granting permission. Qualcomm is buying certain Huawei U.S. patents, which the companies identify as covering compute, AI and networking. The source does not say how many patents are involved, which ones, or what Qualcomm is paying.

What Each Side Says

Alan Fan, Huawei's Chief Intellectual Property Officer, pointed to Huawei's contributions to 4G and 5G standards, citing polar codes, a signal transmission technique he described as near the physical limit. John Han, who runs Qualcomm Technology Licensing, said the deal reaffirms industry recognition of Qualcomm's 5G leadership and the success of its 5G SEP licensing program. Both statements are the companies' own framing of a deal they negotiated. The announcement is the only source here, and it carries no independent analysis of who gained more.

The Playbook: What a Sensible Operator Does This Month

If you build or buy devices, networking gear or AI hardware, resist two reflexes. The first is to assume you are now covered. A bilateral license protects the two parties and, depending on its terms, their products. It does not automatically extend to suppliers, customers or anyone downstream. Check your own contracts and indemnities before assuming anything.

The second mistake is to ignore it. Patents moving between companies change who can assert them. A patent Qualcomm acquires from Huawei is now Qualcomm's to enforce, and any license you hold with Huawei may or may not follow it. Ask your counsel to inventory which Huawei patents you rely on or have been approached about, and note the closing condition: until regulators approve, nothing announced here has taken effect.

Do not rewrite budgets or product plans on this announcement alone. Wait for terms, scope and the regulatory outcome.

Questions You Should Be Asking

• Which of the Huawei U.S. patents Qualcomm is buying overlap with technology in our products, and do any existing licenses we hold with Huawei survive the transfer?
• Does the cross-license reach our suppliers and customers, or only the two signatories and their own products?
• Which regulators must approve the closing, and what happens to the arrangement if one declines or imposes conditions?
• The companies say licensing is consistent with FRAND principles. Who is able to verify that, given the terms are not public?
• If AI and compute patents are now concentrated at Qualcomm, does that change what a chip or device vendor can expect to be asked to pay?

What To Watch Next

The signal that matters is the regulatory approval itself: whether the transaction closes, how long it takes, and whether any conditions are published. Until then, terms stay private and the practical effect on third parties stays unknown. Any later disclosure of which patents changed hands will tell you far more than this announcement does.